
- BioPharm International-02-01-2014
- Volume 27
- Issue 2
Defining Quality Metrics is No Easy Task
ISPE and PDA take on the challenge of recommending quality metrics.
In its Strategic Plan for Preventing and Mitigating Drug Shortages, FDA reiterated its position that shortages of drugs and biologics pose a significant public health threat and preventing drug shortages remains a top priority. The agency also identified two central goals: improving mitigation response to shortages and implementing strategies for the long-term prevention of shortages by focusing on the root causes of the shortages.
FDA cites some recent success in working with manufacturers to mitigate shortages and restore lost production. A six-fold increase in early notification of possible shortages, combined with allocation of additional FDA resources, resulted in a decrease in the number of new shortages from 251 in 2011 to 117 in 2012, FDA reports. Despite this improvement, there is still much work to be done, particularly to address manufacturing and quality issues that are the root cause of drug shortages.
FDA strategies to move toward long-term prevention include the establishment of a proposed Office of Pharmaceutical Quality within the Center for Drug Evaluation and Research (CDER) and the establishment of risk-based approaches to identify early warning signs for manufacturing and quality problems. In response to FDA calls for input on a third strategy, the broader use of manufacturing metrics to assist in the evaluation of manufacturing quality, two industry associations have offered proposals for potential metrics programs.
In December 2013, the International Society of Pharmaceutical Engineers (ISPE) released
The ISPE team, with representatives from pharmaceutical organizations, identified metrics that are mostly site-based. The intention, ISPE reports, is to start with indicator metrics and consider refinement in subsequent phases to better link to FDA’s six systems used in the inspection program and to products.
The initial six metrics, all lagging indicators, are: batch rejection rate, rework and reprocessing rate, confirmed out-of-specification (OOS) rate, unconfirmed OOS rate, critical complaints rate, and % annual product quality reviews complete on time. ISPE also offered definitions for these metrics, suggested alternative metrics, an implementation program, and options for next steps.
The Parenteral Drug Association (PDA) developed a “
These initial efforts of ISPE and PDA to provide some guidance to FDA should be commended. However, there is much work to be done. We will be monitoring developments in future issues of BioPharm International and on our
About the Author
Rita Peters is the editorial director of BioPharm International.
Articles in this issue
over 11 years ago
Novel Expression Systems Opening CMO Opportunitiesover 11 years ago
EMA Collaborates with HTA Assessment Networksover 11 years ago
Tackling the Challenge of HOS Determinationover 11 years ago
The Affordable Care Act's Impact on Innovation in Biopharmaover 11 years ago
Cytotoxicity Risks in Single-use Media and Bioreactor Containersover 11 years ago
BioPharm International, February 2014 Issue (PDF)Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.